Inhibitors of cyclooxygenase-2 (COX-2) suppressed the proliferation and differentiation of human leukaemia cell lines

被引:62
|
作者
Nakanishi, Y [1 ]
Kamijo, R [1 ]
Takizawa, K [1 ]
Hatori, M [1 ]
Nagumo, M [1 ]
机构
[1] Showa Univ, Sch Dent, Dept Oral & Maxillofacial Surg 2, Ota Ku, Tokyo 1458515, Japan
关键词
U-937; ML-1; COX-2; inhibitor; NS-398; nabumetone; proliferation; differentiation; G0/G1; arrest;
D O I
10.1016/S0959-8049(01)00160-5
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Prostaglandins (PG) are known to play important roles in the proliferation and differentiation of leukaemia cells. The effect of the inhibitors of cyclooxygenase-2 (COX-2), a rate-limiting enzyme for the synthesis of PG, on the proliferation and differentiation of leukaemia cell lines was investigated. COX-2 inhibitors, NS-398 and nabumetone, suppressed the proliferation of U-937 and ML-1 cells by inducing a G0/G1 cell-cycle arrest. Cell-cycle arrest induced by these COX-2 inhibitors was not associated with an upregulation of the cyclin-dependent kinase inhibitors. COX-2 inhibitors also inhibited the differentiation of these cells induced by interferon-gamma (IFN-gamma), tumour necrosis factor-alpha (TNF-alpha) and retinoic acid (RA). Treatment with NS-398 did not suppress the levels of PGs produced by these cells. Although COX-2 antisense oligonucleotide showed a similar inhibitory effect on these cells, its inhibitory effect was smaller than that of NS-398, These results suggest that COX-2 inhibitors may suppress the proliferation and differentiation of leukaemia cells both via COX-2-dependent and -independent pathways. (C) 2001 Elsevier Science Ltd. All rights reserved.
引用
收藏
页码:1570 / 1578
页数:9
相关论文
共 50 条
  • [31] Selenomethionine inhibits growth and suppresses cyclooxygenase-2 (COX-2) protein expression in human colon cancer cell lines
    Baines, A
    Taylor-Parker, M
    Goulet, AC
    Renaud, C
    Gerner, EW
    Nelson, MA
    CANCER BIOLOGY & THERAPY, 2002, 1 (04) : 370 - 374
  • [32] Up-Regulation of Cyclooxygenase-2 (COX-2) Expression by Temozolomide (TMZ) in Human Glioblastoma (GBM) Cell Lines
    Lombardi, Francesca
    Augello, Francesca Rosaria
    Artone, Serena
    Gugu, Mitilda Karoli
    Cifone, Maria Grazia
    Cinque, Benedetta
    Palumbo, Paola
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2022, 23 (03)
  • [33] Evaluation of glycolamide esters of indomethacin as potential cyclooxygenase-2 (COX-2) inhibitors
    Khanna, Smriti
    Madan, Manjula
    Vangoori, Akhila
    Banerjee, Rahul
    Thaimattam, Ram
    Basha, S. K. Jafar Sadik
    Ramesh, Mullangi
    Casturi, Seshagiri Rao
    Pal, Manojit
    BIOORGANIC & MEDICINAL CHEMISTRY, 2006, 14 (14) : 4820 - 4833
  • [35] Effect of cyclooxygenase-2 (COX-2) inhibitors in various animal models of epilepsy
    Kulkarni, S. K.
    Dhir, A.
    Naidu, P. S.
    INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY, 2006, 9 : S133 - S133
  • [36] Cyclooxygenase-2 (COX-2) inhibitors: future therapeutic strategies for epilepsy management
    Chitra Rawat
    Samiksha Kukal
    Ujjwal Ranjan Dahiya
    Ritushree Kukreti
    Journal of Neuroinflammation, 16
  • [37] Bioactivity of dihydropyrimidinone derivatives as inhibitors of cyclooxygenase-2 (COX-2): an in silico approach
    Ul Haq, Kautsar
    Sa'adah, Nur Lailatus
    Siswanto, Imam
    Suwito, Hery
    RSC ADVANCES, 2023, 13 (49) : 34348 - 34357
  • [38] Selective Cyclooxygenase-2 (COX-2) Inhibitors Used for Preventing or Regressing Cancer
    Pereira, Ricardo de Souza
    RECENT PATENTS ON ANTI-CANCER DRUG DISCOVERY, 2009, 4 (02) : 157 - 163
  • [39] Fimbristylis aestivalis Vahl: a potential source of cyclooxygenase-2 (COX-2) inhibitors
    Talukder, Saduddin
    Ahmed, Khondoker Shahin
    Hossain, Hemayet
    Hasan, Tarek
    Liya, Israt Jahan
    Amanat, Muhammed
    Nahar, Nurun
    Shuvo, Md Sadikur Rahman
    Daula, A. F. M. Shahid Ud
    INFLAMMOPHARMACOLOGY, 2022, 30 (06) : 2301 - 2315
  • [40] Selective cyclooxygenase-2 (COX-2) inhibitors and potential risk of cardiovascular events
    Mukherjee, D
    BIOCHEMICAL PHARMACOLOGY, 2002, 63 (05) : 817 - 821